Quralis News

QurAlis wins the Pfizer Golden Ticket!

QurAlis has won the Pfizer Golden Ticket! to read more click here.

Read More

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

The man had come for a third opinion. Other doctors had told him he had amyotrophic lateral sclerosis, or ALS, a neuromuscular disease that causes progressive paralysis, but he didn’t believe them. Read the full story here.

Read More

Discovery Advances

We successfully generated a crystal structure of one of our early lead molecules in complex with our molecular target.  This structure is currently being used to design new compounds.

Read More

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

CAMBRIDGE, Mass., April 5, 2018. QurAlis Corporation, a new private biotech company focused on developing precision solutions to cure ALS, today announced the addition of biotech investors MP Healthcare Venture Management (MPH), Amgen Ventures, and Alexandria Venture Investments, who have joined the fight to cure Amyotrophic Lateral Sclerosis (ALS). ALS, the most common motor neuron…

Read More

QurAlis has won the Amgen Golden Ticket at LabCentral

CAMBRIDGE, Mass., Dec. 15, 2017  QurAlis was chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge R&D and Operations facility on Dec. 11, 2017. Five finalists pitched their business plan to attendees where the audiences’ input represented one vote of the overall results, along with…

Read More